In one of the drug industry's more revealing scandals in a while, Merck and Schering-Plough are struggling to rescue two new cholesterol drugs from evidence that they're useless at fighting heart disease and charges that the two companies deliberately sat on the bad news for roughly a year. ...
In one of the drug industry's more revealing scandals in a while, Merck and Schering-Plough are struggling to rescue two new cholesterol drugs from evidence that they're useless at fighting heart disease and charges that the two companies deliberately sat on the bad news for roughly a year. ...
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/research/4e90d7/vytorin_wave_two) has announced the addition of the "Vytorin: Wave Two - Impact of ENHANCE Trial" report to their offering. A Survey of One-Hundred Three US-based PCP's and Cardiologists Deliverable: Survey with key findings. Study Description: Topic:...
Lawsuit claims manufacturers misled consumers about the use of Zetia and Vytorin. SEATTLE, June 10 /PRNewswire/ -- Last week the U.S. District Court in New Jersey appointed Hagens Berman, along with four other firms, co-counsel in a case against Schering-Plough and Merck which claims the...
Jami Rubin Morgan Stanley Stock: Schering-Plough Price target $20.00 Share price (as of April 4,2008) $16.12 52-Week Range $33.81-13.83 Significant stock sell-off for both Schering-Plough (-25%) and Merck (-15%) after the American College of Cardiology ACC conference thus far looks drastically disproportionate to the...
ON JAN. 14, Schering-Plough released preliminary results of its ENHANCE clinical trial, finding that Vytorin (Zocor/Zetia) did nothing more than generic Zocor alone to slow the progression of plaques-in the carotid arteries of a smallish number of patients with a familial form of hypercholesterolemia who had previously been on statins....
The European Federation of Pharmaceutical Industries and Associations said it doesn't want "push" TV, radio and print mass media for Rx drug info. Instead, the trade group proposed "push" info to be allowed only for disease awareness and "pull" info on specific medicines be allowed online. A New England...
Even if I had another topic planned, how could I not write this month about Zetia? Another example of panacea to panic, another billion dollar drug toileted based on preliminary studies. More than 4 million Americans taking this drug or the combination drug Vytorin Zetia plus Zocor now not sure...
KENILWORTH, N.J., April 24 /PRNewswire-FirstCall/ -- Schering-Plough Corporation announced today that Chairman and CEO Fred Hassan purchased just over $2 million of Schering-Plough common stock, or 110, 000 shares at an average purchase price of $18.26 per share. "As I said when I announced my intention to...
PHILADELPHIA -- According to follow-up research from Cognet-X, Inc., conducted in the first week of April, pharmacy and medical executives at leading health plans still do not foresee widespread changes in how their organizations will cover Merck/Schering-Plough's cholesterol reducer Vytorin. Among the reasons: more than three-quarters of those...
Sermo Survey of Hundreds of Physicians Reveals Unexpected Outcomes CAMBRIDGE, Mass. -- Sermo (http://www.sermo.com), the largest physician-only online community, today announced the results of a physician survey prompted by the swirl of media coverage following the release of ENHANCE trial data at the recent American College of Cardiology...
IN the turmoil swirling around the cholesterol medication Vytorin, an important message has been lost: This is not a bad drug. But its manufacturers -- Schering-Plough and Merck -- have handled its development badly, undermining confidence in the industry and a drug that could yet prove to...
IN THE TURMOIL swirling around the cholesterol medication Vytorin, an important message has been lost: This is not a bad drug. But its manufacturers -- Schering-Plough and Merck -- have handled its development badly, undermining confidence in the industry and a drug that could yet prove to...
CHICAGO -- Fitch Ratings has placed Schering-Plough Corp.'s (Schering-Plough) (NYSE:SGP) ratings on Rating Watch Negative. The action applies to approximately $11.98 billion of outstanding debt. The Rating Watch reflects Fitch's concern that Schering-Plough will be unable to reduce leverage, total debt-to-EBITDA, to below 2.0 times x by the...
CHICAGO -- A trial of AstraZeneca's heart drug Crestor was stopped early because the drug proved so effective that the study's independent monitors felt it would be unethical to withhold treatment from half the volunteers, company officials said Monday. "We're excited," says Lisa Nanfra of AstraZeneca. ...
Schering-Plough's "49 Plan," an aggressive seven-week sales push allegedly aimed at shoring up Zetia prescriptions by offering docs meals and entertainment, came under congressional scrutiny after it was reported on by the StarLedger blog Pharmalot. The FDA made deputy commissioner Janet Woodcock permanent director of the Center for Drug...
CHICAGO -- Leading doctors urged a return to older, tried-and- true treatments for high cholesterol after hearing full results Sunday of a failed trial of Vytorin and related drug Zetia. Millions of Americans already take the drug or one of its components, Zetia. But doctors were stunned...
CHICAGO -- The blockbuster drugs Vytorin and Zetia should be used only after all other cholesterol-lowering drugs fail until research proves that the medications work, a panel of heart specialists recommended here Sunday. The panel, convened by the American College of Cardiology, based its assessment on detailed evidence...
CHICAGO AFP — New clinical trials have increased doubts about the efficiency of Merck and Schering-Plough's prized anti-cholesterol drug Vytorin and its ability to fight cardiovascular disease, according to medical data released here. A group of distinguished cardiologists recommended taking high doses of statins to reduce bad cholesterol...
POMONA, Calif. -- Use of a controversial new cholesterol-lowering drug, ezetimibe (trade names: Zetia, Ezetrol, Vytorin), has increased in the United States, far beyond that seen in Canada, where direct-to-consumer advertising DTCA is prohibited and there is more government regulation of drug reimbursement in publicly-funded drug formularies. Worldwide sales for...
Articles 2008-03-30
<< Previous
page 1 of 1
Next >>
Premier Vendor Content
Whitepapers, webcasts & resources from our Power Center Sponsors
